Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced that ANJESO™ (meloxicam) injection, the only 24-hour, intravenous (IV) COX-2 preferential …
Read More